Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma

Pamela B. Allen*, Jane N. Winter

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Purpose of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients. Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study. Summary: The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.

Original languageEnglish (US)
Article number39
JournalCurrent oncology reports
Volume21
Issue number5
DOIs
StatePublished - May 1 2019

    Fingerprint

Keywords

  • Brentuximab vedotin
  • Checkpoint inhibitors
  • Hodgkin lymphoma
  • Immunotherapy
  • Nivolumab
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology

Cite this